ArticleJournal of cardiothoracic surgery2025
Plasma metabolites as biomarkers for screening and differential diagnosis of lung cancer.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, there is a lack of satisfactory biomarkers for lung cancer screening and differential diagnosis. Metabolomics can detect the differences of metabolites in different pathological states, which may be helpful in the identification of lung cancer.
methodsPatients with pulmonary nodules were divided into two groups: benign pulmonary nodules (BPN) and primary lung cancer (PLC). Healthy population group(HPG) was enrolled. Half of PLC and HPG were selected as the testing subset and the validating subset, respectively. Two groups with different pulmonary lesions were compared with HPG, respectively, and compared with each other. Univariate and multivariate data statistical analysis method was used to select the metabolites. Their discriminating ability was verified by the ROC curve in the validating subset.
resultsThe testing subset was comprised of BPN(n = 32), PLC(n = 80), and HPG(n = 48). The significant metabolites selected by the comparison of PLC and HPG were 1-salicylate glucuronide, s-nitrosoglutathione, and dihydrocaffeic acid 3-O-glucuronide. Their AUC of ROC was all greater than 0.95(0.957-0.995) in the validating subset, which indicated they had a strong ability to differentiate PLC from HPG. From the comparison of the two pulmonary nodule groups with each other, three metabolites with good sensitivity and specificity were selected, whose discriminating ability of PLC from BPN was satisfactory.
conclusionThrough the research of plasma metabolomics, some significant metabolites were detected among PLC, BPN, and HPG, which have the potential to be the promising biomarkers for lung cancer screening and differential diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.